Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Canopy Growth Reports Third Quarter Fiscal 2020 Financial Results

      This image opens in the lightbox

      News provided by

      Canopy Growth Corporation

      14 Feb, 2020, 11:00 GMT

      Share this article

      Share this article


      Generated $124 million Net Revenue, up from $76 million in Q2 2020
      Excluding portfolio restructuring charges in Q2 2020, Net Revenue up 13%
      Achieved Gross Margin of 34%
      Total Operating Expenses down 14% versus the prior quarter
      Adjusted EBITDA loss decreases to $92 million

      SMITHS FALLS, Ontario, Feb. 14, 2020 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NYSE: CGC) today announced its financial results for the third quarter ended December 31, 2019.  All financial information in this press release is reported in millions of Canadian dollars, unless otherwise indicated.


      Third Quarter Fiscal 2020 Financial Summary



      Gross revenue1

      Net revenue

      Gross margin2

      Adjusted EBITDA3

      Free cash flow4

      Reported

      $135.6

      $123.8

      34%

      $(91.7)

      $(359.6)

      % change vs. Q2 2020

      15%

      62%

      NM

      41%

      16%

      % change vs. Q3 2019

      39%

      49%

      800 bps

      -23%

      -20%

      1 Excludes the impact of other revenue adjustments in Q2 2020, which represent the Company's determination of returns and pricing adjustments.

      2 Gross margin is before fair value impacts in cost of sale, and is a non-IFRS measure. See "Non-IFRS Measures" below.

      3 Adjusted EBITDA is a non-IFRS measure. See "Non-IFRS Measures" below.

      4 Free cash flow is defined as operating cash flow less capital expenditures, and is a non-IFRS measure. See "Non-IFRS Measures" below.

      Third Quarter Fiscal 2020 Corporate Financial Highlights

      • Revenues: Reported Net Revenues increased 62% over Q2 2020, or 13% excluding the impact of portfolio restructuring charges. Gross Recreational B2B revenue increased 8% over prior quarter due, in part, to over 140 stores becoming active in the quarter and higher sales of premium dried flower and pre-roll joints. Our acquired businesses including Storz & Bickel and This Works also performed well, contributing to organic growth this quarter.
      • Gross margin: Gross margin before fair value impacts was 34%. Gross margin performance in quarter benefited from lower period costs due to higher facility utilization
      • Operating expenses: Total operating expenses decreased 14% versus Q2 2020 primarily due to a $20 million reduction in G&A expenses and over $31 million lower stock-based compensation versus the prior quarter
      • Adjusted EBITDA: Adjusted EBITDA loss of $92 million, a $64 million narrower loss versus Q2 2020 driven by higher sales, improved gross margins and lower operating expenses
      • Cash Position: Gross cash balance was $2.3 billion, down from $2.7 billion in Q2 2020, reflecting the EBITDA loss, capital investments and M&A

      Third Quarter Fiscal 2020 Business & Operational Highlights

      • Maintained leading market share in retail, at an estimated 22%, of the Canadian recreation market as we saw a strong demand for both premium and value priced dried flower and pre-rolled joints
      • Continued market share gains and increase in the number of patients, to over 76,700, in the Canadian medical cannabis market
      • Named David Klein as new Chief Executive Officer
      • Completed first shipments of cannabis-infused edible chocolates and JUJU Power 510 batteries in December 2019
      • Storz & Bickel expanded product line with launch of Crafty+ vaporizer in November 2019
      • Announced initial line of First & Free Hemp-derived CBD products and began sales online through www.firstandfree.com, one quarter ahead of Q4 2020 target

      "In Q3 we executed across Canada, in our international markets and in our strategic acquisitions to drive revenue growth," said David Klein, CEO. "We have a lot of work to do.  We are eager to capitalize on the opportunity to create an unassailable position through a tight focus on the consumer and on critical markets."

      "We delivered significant gross improvement in the third quarter driven by stronger revenues and higher capacity utilization. Actions taken earlier this year are expected to meaningfully reduce stock-based compensation in FY21, and we have started to implement tighter cost controls across the organization," said Mike Lee, EVP & CFO. "We plan to take further steps to reduce our costs and right-size our business to ensure that we can generate a healthy margin profile and cash generation in the coming years."

      Third Quarter Fiscal 2020 Financial and Operational Review



      Q3

      2020

      Q2

      2020

      %

      Change

      Q3

      2019

      %

      Change

      Canadian recreational cannabis






      - Business to business1

      $53.5

      $49.4

      8%

      $60.1

      -11%

      - Business to consumer

      $15.2

      $13.1

      16%

      $11.5

      32%

      Canadian medical cannabis

      $14.8

      $14.1

      5%

      $15.9

      -7%

      Canadian cannabis

      $83.5

      $76.6

      9%

      $87.5

      -5%

      International medical cannabis

      $18.7

      $18.1

      3%

      $2.7

      593%

      Cannabis gross revenue excluding other revenue adjustments

      $102.2

      $94.7

      8%

      $90.2

      13%

      Other revenue

      $33.4

      $23.6

      42%

      $7.5

      345%

      Gross revenue excluding other revenue adjustments

      $135.6

      $118.3

      15%

      $97.7

      39%

      Other revenue adjustments2

      $-

      $32.7

      -100%

      $-

      NM

      Excise taxes3

      $11.8

      $9.0

      31%

      $14.7

      -20%

      Net revenue

      $123.8

      $76.6

      62%

      $83.0

      49%

      1 Excludes the impact of other revenue adjustments.

      2 Other revenue adjustments represent the Company's determination of returns and pricing adjustments.

      3 Excise taxes is presented net of the impact from other revenue adjustments.

      Canadian Cannabis  

      • Recreational B2B sales increased 8% over Q2 2020, due to over 140 stores becoming active in the quarter and higher sales of premium dried flower and pre-roll joints
      • Recreational B2C sales increased 16% over prior quarter, due in part to an 11% increase in same store sales
      • Medical sales increased 5% over the prior quarter primarily attributable to the broadening of our brand and product offerings, including the availability of products from additional CraftGrow partners, as well as an increase in number of customers to over 76,700.

      International Cannabis

      • C3 revenue increased 5% over Q2 2020
      • Germany cannabis sales higher than expected due to opportunistic sales into the German market to fill a supply gap that resulted from a regulatory enforced sales halt of cannabis products offered by another vendor

      Strategic Acquisitions

      • Storz & Bickel vaporizer revenue increased 46% over Q2 2020 due to solid organic growth and seasonal sales
      • This Works revenue increased 42% over prior quarter due to strong organic growth

      Third Quarter Fiscal 2020 Cannabis Product Revenue Highlights



      Q3

      2020

      Q2

      2020

      %

      Change

      Q3

      2019

      %

      Change

      Canadian recreational - Business to business






      Dry cannabis

      $55.8

      $47.4

      18%

      $39.3

      42%

      Cannabis oil and softgels excluding other revenue adjustments

      $3.0

      $2.0

      50%

      $20.8

      -86%

      Other revenue adjustments1

      $(5.3)

      $(32.7)

      -84%

      $-

      NM


      $53.5

      $16.7

      220%

      $60.1

      -11%

      Canadian recreational - Business to consumer






      Dry cannabis

      $13.5

      $11.6

      16%

      $10.9

      24%

      Cannabis oil and softgels

      $1.7

      $1.5

      13%

      $0.6

      183%


      $15.2

      $13.1

      16%

      $11.5

      32%

      Canadian medical






      Dry cannabis

      $5.3

      $5.5

      -4%

      $8.1

      -35%

      Cannabis oil and softgels

      $9.5

      $8.6

      10%

      $7.8

      22%


      $14.8

      $14.1

      5%

      $15.9

      -7%

      International medical






      Dry cannabis

      $3.9

      $4.1

      -5%

      $2.7

      44%

      Cannabis oil and softgels

      $14.8

      $14.0

      6%

      $-

      NM


      $18.7

      $18.1

      3%

      $2.7

      593%

      1 Other revenue adjustments represent the Company's determination of returns and pricing adjustments.

      Third Quarter Fiscal 2020 Adjusted EBITDA



      Q3

      2020

      Q2

      2020

      %

      Change

      Q3

      2019

      %

      Change

      Adjusted EBITDA1

      $(91.7)

      $(155.7)

      41%

      $(74.8)

      -23%

      Attributed as follows:






      - Operations and corporate overhead

      $(44.4)

      $(109.0)

      59%

      $(52.8)

      16%

      - Strategic investments and business development

      $(39.1)

      $(36.2)

      -8%

      $(8.9)

      -339%

      - Non-operating or under-utilized facilities

      $(8.2)

      $(10.5)

      22%

      $(13.1)

      37%

      1 Adjusted EBITDA is a non-IFRS measure. See "Non-IFRS Measures" below.

      Non-IFRS Measures

      Gross margin percentage, before fair value impacts in cost of sales, a non-IFRS measure, is a key operational metric that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies.  This measure is calculated as net revenue less inventory production costs expensed to cost of sales, divided by net revenue, and may be computed from the consolidated statements of operations presented within this news release. 

      Adjusted EBITDA, a non-IFRS measure, is a key operational metric that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. Adjusted EBITDA is calculated as earnings before interest, tax, depreciation and amortization, share-based compensation expense, fair value changes and other non-cash items, and further adjusted to remove acquisition-related costs. The Company attributes Adjusted EBITDA to its operations and corporate overhead, strategic investments and business developments, and non-operating or under-utilized facilities. The Adjusted EBITDA reconciliation is presented within this news release and explained in Management's Discussion & Analysis under "Adjusted EBITDA (Non-IFRS Measure)", a copy of which will be filed on SEDAR.

      Free Cash Flow, a non-IFRS measure, is a key operational metric that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies.  This measure is calculated as net cash provided by (used in) operating activities less purchases and deposits of property, plant and equipment.

      Transition to U.S. GAAP Reporting

      As part of our U.S. financial reporting requirements, Canopy Growth confirmed that, as of September 30, 2019, it no longer met the criteria for qualification as a foreign private issuer because (1) more than 50% of the outstanding voting securities are held by residents of the United States, and (2) the majority of Canopy Growth's directors are United States citizens.

      Therefore, as of April 1, 2020 Canopy Growth will be considered a United States domestic issuer and a large accelerated filer. As a result of this change, as of April 1, 2020, Canopy Growth will be required to prepare its consolidated financial statements, including the Company's March 31, 2020 audited annual consolidated financial statements, in conformity with United States generally accounting principles, with such change being applied retrospectively. The extent of the impact of this change in accounting framework has not yet been quantified. Canopy Growth will also be required to provide an auditor attestation report under Section 404(b) of the Sarbanes-Oxley Act.

      This press release is intended to be read in conjunction with the Company's Unaudited Condensed Interim Consolidated Financial Statements ("Financial Statements) and Management Discussion & Analysis ("MD&A) for the three and nine months ended December 31, 2019, which will be filed on SEDAR (www.sedar.com) and will be available at www.canopygrowth.com. The basis of financial reporting in the Financial Statements and MD&A is in thousands of Canadian dollars, unless otherwise indicated.

      Webcast and Conference Call Information

      The Company will host a conference call and audio webcast with David Klein, CEO and Mike Lee, CFO at 10:00 AM Eastern Time on February 14, 2020.

      Webcast Information
      A live audio webcast will be available at:
      https://event.on24.com/wcc/r/2171215/8311836AC24F7988B042B4BB0FA5622A

      Replay Information
      A replay of the call will be accessible by webcast, until 11:59 PM ET on May 14, 2020, at
      https://event.on24.com/wcc/r/2171215/8311836AC24F7988B042B4BB0FA5622A

      About Canopy Growth Corporation
      Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through the Company's subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has operations in over a dozen countries across five continents.

      The Company's medical division, Spectrum Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics.

      The Company operates retail stores across Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and loyal following by focusing on quality products and meaningful customer relationships.

      From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eleven licensed cannabis production sites with over 5.2 million square feet of production capacity, including over one million square feet of GMP certified production space. For more information visit www.canopygrowth.com

      Notice Regarding Forward Looking Statements
      This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to the Company's expectations with respect to future harvests, the Company's expectation for additional finished inventory available for sale in future quarters, bringing CBD products to market by the end of fiscal 2020, the accelerated market expansion for Acreage, the anticipated benefits of the rebranding of Spectrum Therapeutics on the Company's market share, the potential opportunity for cannabis products in Europe and the anticipated Increase in Canadian and Danish product availability, the anticipated increased sales from Storz & Bickel, the expectation that facilities will be fully operational in the months ahead, the launch of new CBD consumer products and brands in fiscal 2020, the timing for implementation of the transaction with Acreage. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including changes in laws, regulations and guidelines; compliance with laws; international laws; operational, regulatory and other risks; execution of business strategy; management of growth; difficulty to forecast; reliance on licences; risks inherent in an agricultural business; contracts with provincial and territorial governments; constraints on marketing products; risks inherent in acquisitions and investments; expansion into foreign jurisdictions; governmental regulations; cannabis is a controlled substance in the United States; Farm Bill risks; assumptions as to the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory and court approvals for the transaction with Acreage; and such risks contained in the Company's management information circular of the Company dated May 17, 2019 and in the annual information form dated June 24, 2019 and filed with Canadian securities regulators and available on the Company's issuer profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.


      CANOPY GROWTH CORPORATION

      CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

      UNAUDITED

      December 31,

      March 31,

      (Expressed in CDN $000's)

      2019

      2019






      Assets





      Current assets





      Cash and cash equivalents

      $

      1,561,664

      $

      2,480,830

      Marketable securities


      705,921


      2,034,133

      Amounts receivable


      108,822


      106,974

      Biological assets


      59,107


      78,975

      Inventory


      622,575


      262,105

      Prepaid expenses and other current assets


      114,637


      107,123



      3,172,726


      5,070,140






      Investments in equity method investees


      123,077


      112,385

      Other financial assets


      351,952


      363,427

      Property, plant and equipment


      1,725,333


      1,096,340

      Intangible assets


      567,185


      519,556

      Goodwill


      2,068,696


      1,544,055

      Other long-term assets


      37,073


      25,902







      $

      8,046,042

      $

      8,731,805






      Liabilities





      Current liabilities





      Accounts payable and accrued liabilities

      $

      225,181

      $

      226,533

      Current portion of long-term debt


      21,652


      103,716

      Other current liabilities


      171,476


      81,414



      418,309


      411,663






      Long-term debt


      536,107


      842,259

      Deferred tax liability


      65,733


      96,031

      Share repurchase credit liability


      1,301,322


      -

      Other long-term liabilities


      194,737


      140,404








      2,516,208


      1,490,357






      Shareholders' equity





      Share capital


      6,359,643


      6,026,618

      Other reserves


      2,768,725


      1,673,472

      Accumulated other comprehensive income


      (45,904)


      28,630

      Deficit


      (3,826,095)


      (777,087)






      Equity attributable to Canopy Growth Corporation


      5,256,369


      6,951,633






      Non-controlling interests


      273,465


      289,815






      Total equity


      5,529,834


      7,241,448







      $

      8,046,042

      $

      8,731,805


      CANOPY GROWTH CORPORATION

      CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS

      FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2019 AND 2018

      UNAUDITED

      Three months ended

      Nine months ended


      December 31,

      December 31,

      December 31,

      December 31,

      (Expressed in CDN $000's except share amounts)

      2019

      2018

      2019

      2018


      (Restated - see note 2(d))

      (Restated - see note 2(d))






      Revenue

      $135,546

      $97,703

      $324,558

      $146,946

      Excise taxes

      11,782

      14,655

      33,699

      14,655






      Net revenue

      123,764

      83,048

      290,859

      132,291






      Inventory production costs expensed to cost of sales

      81,953

      61,329

      241,456

      90,358






      Gross margin before the undernoted

      41,811

      21,719

      49,403

      41,933






      Fair value changes in biological assets included in inventory sold and other charges

      60,546

      28,105

      175,765

      105,989

      Unrealized gain on changes in fair value of biological assets

      (78,964)

      (22,267)

      (300,303)

      (90,500)






      Gross margin

      60,229

      15,881

      173,941

      26,444






      Sales and marketing

      62,104

      48,324

      171,814

      107,199

      Research and development

      20,795

      5,264

      41,191

      7,964

      General and administration

      67,385

      46,088

      217,517

      102,777

      Acquisition-related costs

      3,256

      4,520

      19,000

      9,606

      Share-based compensation expense

      56,763

      40,062

      217,611

      108,159

      Share-based compensation expense related to acquisition milestones

      4,916

      23,849

      24,311

      81,674

      Depreciation and amortization

      16,530

      5,015

      42,953

      11,640






      Operating expenses

      231,749

      173,122

      734,397

      429,019






      Loss from operations

      (171,520)

      (157,241)

      (560,456)

      (402,575)






      Loss on extinguishment of warrants

      -

      -

      (1,176,350)

      -

      Other income (expense), net

      24,903

      233,142

      (51,759)

      54,445

      Total other income (expense), net

      24,903

      233,142

      (1,228,109)

      54,445






      (Loss) income before income taxes

      (146,617)

      75,901

      (1,788,565)

      (348,130)






      Income tax recovery (expense)

      22,451

      (1,041)

      8,611

      1,398






      Net (loss) income

      $(124,166)

      $74,860

      $(1,779,954)

      $(346,732)






      Net (loss) income attributable to:





      Canopy Growth Corporation

      $(120,969)

      $67,582

      $(1,778,208)

      $(349,831)

      Non-controlling interests

      (3,197)

      7,278

      (1,746)

      3,099


      $(124,166)

      $74,860

      $(1,779,954)

      $(346,732)






      (Loss) earnings per share, basic





      Net (loss) income per share, basic:

      $(0.35)

      $0.22

      $(5.13)

      $(1.45)

      Weighted average number of outstanding common shares:

      348,530,622

      303,281,549

      346,877,660

      241,806,351






      Loss per share, diluted





      Net loss per share, diluted:

      $(0.35)

      $(0.38)

      $(5.13)

      $(1.45)

      Weighted average number of outstanding common shares, diluted:

      348,530,622

      315,974,639

      346,877,660

      242,044,821



      CANOPY GROWTH CORPORATION

      CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS  

      FOR THE NINE MONTHS ENDED DECEMBER 31, 2019 AND 2018  

      UNAUDITED  


      December 31,


      December 31,

      (Expressed in CDN $000's)  


      2019


      2018






      Net inflow (outflow) of cash related to the following activities:










      Operating





      Net loss

      $

      (1,779,954)

      $

      (346,732)

      Adjustments for:





      Depreciation of property, plant and equipment


      57,926


      15,703

      Amortization of intangible assets


      26,680


      7,869

      Share of loss on equity investments


      6,668


      9,021

      Fair value changes in biological assets included in inventory sold and other charges


      175,765


      105,989

      Unrealized gain on changes in fair value of biological assets


      (300,303)


      (90,500)

      Share-based compensation


      241,922


      194,686

      Other assets


      -


      (16,908)

      Loss on extinguishment of warrants


      1,176,350


      -

      Other income and expense


      93,162


      (44,476)

      Income tax recovery


      (8,611)


      (1,398)

      Non-cash foreign currency


      (3,945)


      1,394

      Changes in non-cash operating working capital items


      (233,918)


      (129,547)






      Net cash used in operating activities


      (548,258)


      (294,899)






      Investing





      Purchases and deposits of property, plant and equipment


      (610,858)


      (495,236)

      Purchases of intangible assets


      (7,800)


      (40,140)

      Redemption (purchase) of marketable securities, net


      1,324,682


      (802,247)

      Investments in equity method investees


      (4,719)


      (27,201)

      Investments in other financial assets


      (46,647)


      (74,071)

      Premium paid for Acreage Call Option


      (395,190)


      -

      Net cash outflow on acquisition of non-controlling interests


      -


      (1,996)

      Net cash outflow on acquisition of subsidiaries


      (511,080)


      (344,472)

      Payment of acquisition related liabilities


      (29,837)


      -






      Net cash used in investing activities


      (281,449)


      (1,785,363)






      Financing





      Payment of share issue costs


      (245)


      (18,617)

      Proceeds from issuance of common shares and warrants


      -


      5,072,500

      Proceeds from issuance of shares by Canopy Rivers


      1,062


      91,218

      Proceeds from exercise of stock options


      39,149


      28,730

      Proceeds from exercise of warrants


      446


      18,684

      Issuance of long-term debt


      10,268


      600,000

      Payment of long-term debt issue costs


      -


      (16,380)

      Payment of interest on long-term debt


      (13,738)


      -

      Repayment of lease obligations


      (9,331)


      (2,728)

      Repayment of long-term debt


      (112,705)


      (3,499)






      Net cash (used) provided by financing activities


      (85,094)


      5,769,908






      Effect of exchange rate changes on cash and cash equivalents


      (4,365)


      103,664






      Net cash (outflow) inflow


      (919,166)


      3,793,310

      Cash and cash equivalents, beginning of period


      2,480,830


      322,560






      Cash and cash equivalents, end of period

      $

      1,561,664

      $

      4,115,870


      Adjusted EBITDA1 Non-IFRS Measure

      Three months ended

      (In CDN$000's)

      December 31,

      2019

      December 31,

      2018






      Adjusted EBITDA1 Reconciliation





      Loss from operations - as reported

      $

      (171,520)

      $

      (157,241)






      IFRS fair value accounting related to biological assets and inventory

      Fair value changes in biological assets included in inventory sold and other charges


      60,546


      28,105

      Unrealized gain on changes in fair value of biological assets


      (78,964)


      (22,267)



      (18,418)


      5,838

      Share-based compensation expense (per statements of cash flows)


      61,679


      64,179

      Acquisition-related costs


      3,256


      4,520

      Depreciation and amortization (per statements of cash flows)


      33,342


      7,890



      98,277


      76,589

      Adjusted EBITDA

      $

      (91,661)

      $

      (74,814)





      Nine months ended

      (In CDN$000's)

      December 31,

      2019

      December 31,

      2018






      Adjusted EBITDA1 Reconciliation





      Loss from operations - as reported

      $

      (560,456)

      $

      (402,575)






      IFRS fair value accounting related to biological assets and inventory

      Fair value changes in biological assets included in inventory sold and other charges


      175,765


      105,989

      Unrealized gain on changes in fair value of biological assets


      (300,303)


      (90,500)



      (124,538)


      15,489

      Share-based compensation expense (per statements of cash flows)


      241,922


      194,686

      Acquisition-related costs


      19,000


      9,606

      Depreciation and amortization (per statements of cash flows)


      84,606


      23,572



      345,528


      227,864

      Adjusted EBITDA

      $

      (339,466)

      $

      (159,222)

      1 Adjusted EBITDA is earnings before interest, tax, depreciation and amortization, share-based compensation expense, fair value changes and other non-cash items, and further adjusted to remove acquisition-related costs.

      Contact:
      Kyna Boyce
      Media Relations
      media@canopygrowth.com
      613-485-2480

      Judy Hong
      Vice President, Investor Relations (USA)
      Judy.hong@canopygrowth.com

      Tyler Burns
      Vice President, Investor Relations (Canada)
      Tyler.burns@canopygrowth.com
      855-558-9333 ext. 122

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.